Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

Robinson, 2005, Advances in malignant mesothelioma, N Engl J Med, 353, 1591, 10.1056/NEJMra050152 Ceresoli, 2007, Multidisciplinary treatment of malignant pleural mesothelioma, Oncologist, 12, 850, 10.1634/theoncologist.12-7-850 Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136 Ceresoli, 2010, Second-line treatment for malignant pleural mesothelioma, Cancer Treat Rev, 36, 24, 10.1016/j.ctrv.2009.09.003 Jassem, 2008, Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma, J Clin Oncol, 26, 1698, 10.1200/JCO.2006.09.9887 Grégoire, 2010, What's the place of immunotherapy in malignant mesothelioma treatments?, Cell Adh Migr, 4, 153, 10.4161/cam.4.1.11361 Cornelissen, 2012, New roads open up for implementing immunotherapy in mesothelioma, Clin Dev Immunol, 2012, 927240, 10.1155/2012/927240 Lebbe, 2012, Five-year survival rates for patients (pts) with metastatic melanoma (MM) treated with ipilimumab (ipi) in phase II trials, Ann Oncol, 23, 9s, 10.1016/S0923-7534(20)33712-1 Maio, 2012, Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (ipi) plus dacarbazine (DTIC) on phase 3 study CA184-024, Ann Oncol, 23, 9s, 10.1016/S0923-7534(20)33681-4 Calabrò, 2010, Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications, Semin Oncol, 37, 460, 10.1053/j.seminoncol.2010.09.006 Lynch, 2012, Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study, J Clin Oncol, 30, 2046, 10.1200/JCO.2011.38.4032 Tarhini, 2013, Tremelimumab: a review of development to date in solid tumors, Immunotherapy, 5, 215, 10.2217/imt.13.9 Ribas, 2013, Phase III randomized, clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, J Clin Oncol, 31, 616, 10.1200/JCO.2012.44.6112 Calabrò, 2015, CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?, Cancer Immunol Immunother, 64, 105, 10.1007/s00262-014-1609-9 Calabrò, 2013, Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial, Lancet Oncol, 14, 1104, 10.1016/S1470-2045(13)70381-4 Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol, 15, 257, 10.1093/annonc/mdh059 Wolchok, 2009, Guidelines for the evaluation of immunotherapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624 Curran, 1998, Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience, J Clin Oncol, 16, 145, 10.1200/JCO.1998.16.1.145 Zucali, 2012, Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey, Lung Cancer, 75, 360, 10.1016/j.lungcan.2011.08.011 Di Giacomo, 2013, Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10mg/kg within an expanded access programme, Cancer Immunol Immunother, 62, 1021, 10.1007/s00262-013-1418-6 Callahan, 2010, Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy, Semin Oncol, 37, 473, 10.1053/j.seminoncol.2010.09.001 Hillegass, 2010, Inflammation precedes the development of human malignant mesothelioma in a SCID mouse zenograft model, Ann NY Acad Sci, 1203, 7, 10.1111/j.1749-6632.2010.05554.x Kao, 2010, High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy, Clin Cancer Res, 16, 5805, 10.1158/1078-0432.CCR-10-2245 Meniawy, 2013, Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma, Br J Cancer, 109, 1813, 10.1038/bjc.2013.504 Kao, 2014, Comment on ‘Neutrophil to lymphocyte ratio in malignant pleural mesothelioma’, Br J Cancer, 111, 2376, 10.1038/bjc.2014.185 Abakay, 2014, The value of inflammatory parameters in the prognosis of malignant mesothelioma, J Int Med Res, 42, 554, 10.1177/0300060513504163